Free Trial
LON:SN

Smith & Nephew (SN) Share Price, News & Analysis

Smith & Nephew logo
GBX 1,033.50 +16.00 (+1.57%)
As of 02/21/2025

About Smith & Nephew Stock (LON:SN)

Key Stats

Today's Range
1,012.50
1,037
50-Day Range
972.80
1,041
52-Week Range
N/A
Volume
2.24 million shs
Average Volume
343,671 shs
Market Capitalization
£11.33 billion
P/E Ratio
37.21
Dividend Yield
2.81%
Price Target
GBX 4,607.50
Consensus Rating
Buy

Company Overview

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Smith & Nephew Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

SN MarketRank™: 

Smith & Nephew scored higher than 75% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Smith & Nephew has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Smith & Nephew has only been the subject of 1 research reports in the past 90 days.

  • Read more about Smith & Nephew's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Smith & Nephew is 37.21, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.43.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Smith & Nephew is 37.21, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.04.

  • Price to Earnings Growth Ratio

    Smith & Nephew has a PEG Ratio of 0.46. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Smith & Nephew has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for SN.
  • Dividend Leadership

    Smith & Nephew is a leading dividend payer. It pays a dividend yield of 3.66%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Smith & Nephew does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Smith & Nephew is 104.41%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Read more about Smith & Nephew's dividend.
  • Short Interest

    There is no current short interest data available for SN.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Smith & Nephew this week, compared to 1 article on an average week.
  • Search Interest

    11 people have searched for SN on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Smith & Nephew to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Smith & Nephew insiders have bought 109.39% more of their company's stock than they have sold. Specifically, they have bought £699,062.40 in company stock and sold £333,863.73 in company stock.

  • Percentage Held by Insiders

    Only 0.19% of the stock of Smith & Nephew is held by insiders.

  • Percentage Held by Institutions

    62.24% of the stock of Smith & Nephew is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Smith & Nephew's insider trading history.
Receive SN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

SN Stock News Headlines

3 steps to start investing with under £300
Ex-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”
Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. Should you sit on the sideline while this is happening?
Smith & Nephew (SN) Receives a Hold from Barclays
See More Headlines

SN Stock Analysis - Frequently Asked Questions

Smith & Nephew's stock was trading at GBX 991.40 at the beginning of the year. Since then, SN stock has increased by 4.2% and is now trading at GBX 1,033.50.
View the best growth stocks for 2025 here
.

Shares of SN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Smith & Nephew investors own include Imperial Brands (IMB), Smith & Nephew (SNN), Barclays (BARC), Lloyds Banking Group (LLOY), GSK (GSK), AstraZeneca (AZN) and Meta Platforms (META).

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
Consumer Goods
CIK
N/A
Fax
N/A
Employees
18,452
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 4,607.50
High Stock Price Target
£145
Low Stock Price Target
GBX 1,180
Potential Upside/Downside
+345.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
£382.79 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£7.08 billion
Cash Flow
GBX 55.31 per share
Book Value
GBX 595.90 per share

Miscellaneous

Outstanding Shares
1,096,260,062
Free Float
N/A
Market Cap
£11.33 billion
Optionable
Not Optionable
Beta
0.62
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (LON:SN) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners